Loading provider…
Loading provider…
Ophthalmology Physician in Los Angeles, CA
NPI: 1194775890Primary Employer
UCLA Stein Eye Institute Westwood
ucla.edu
HQ Phone
Get M.D. Sophie's Phone Numberphone_androidMobile
Get M.D. Sophie's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2005 - 2027
TN State Medical License
2006 - 2008
CA State Medical License

American Board of Ophthalmology
Ophthalmology
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Cornea
2005 - 2006
University of Illinois College of Medicine at Chicago
Residency • Ophthalmology
2002 - 2005
University of Tennessee
Internship • Internal Medicine
2001 - 2002
University of Rochester Medical Center
urmc.rochester.edu
Medical School
Until 2001
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 271 | 531 |
| 2 | 76514Ultrasound of corneal structure and measurement | 164 | 275 |
| 3 | 92286Microscopic evaluation of deep cells of the eye | 94 | 103 |
| 4 | 68761Closure of tear duct opening using plug | 60 | 142 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 37 | 39 |
Authors: Liang, Qingfeng, Tseng, Chi-Hong, Deng, Sophie X
Journal: Am J Ophthalmol
Publication Date: 2020-09-28
Role of CTCF in EGF-Induced Migration of Immortalized Human Corneal Epithelial Cells
Authors: Wang, Ling, Deng, Sophie X, Lu, Luo
Journal: Invest Ophthalmol Vis Sci
Publication Date: 2012-02-23
Presentation, diagnosis and management of limbal stem cell deficiency.
Authors: Sejpal, Kunjal, Bakhtiari, Pejman, Deng, Sophie X
Journal: Middle East Afr J Ophthalmol
Lead Sponsor: University of California, Los Angeles
Collaborators: Dompé Farmaceutici S.p.A
Intervention / Treatment: DRUG: Cenegermin Ophthalmic Solution [Oxervate]
Lead Sponsor: University of California, Los Angeles
Collaborators: National Eye Institute (NEI), California Institute for Regenerative Medicine (CIRM)
Intervention / Treatment: BIOLOGICAL: cLSC, DEVICE: Scleral contact lens (SCL)
Lead Sponsor: Dompé Farmaceutici S.p.A
Intervention / Treatment: OTHER: Placebo, DRUG: rhNGF 20µg/ml